Purpose Activated super Factor V ( super FVa) is a novel engineered FV with excellent prohemostatic efficacy. Super FVa has three APC cleavage site mutations and an interdomain disulfide bond. Stability, pharmacokinetics, and immunogenic and thrombogenic potential are reported here. Methods Stability and circulating half-life were determined after incubation in buffer and human plasma, and after injection into FVIII-deficient mice. Immunogenicity potential was assessed by B-and T-cell specific epitope prediction and structural analysis using surface area and atomic depth computation. Thrombogenic potential was determined by quantification of lung fibrin deposition in wild-type mice after intravenous injection of super FVa (200 U/kg), recombinant human (rh) Tissue Factor (0.4-16 pmol/kg), rhFVIIa (3 mg/kg) or saline. Results FVa retained full activity over 30 h in buffer, the functional half-life in human plasma was 4.9 h, and circulating half-life in FVIII-deficient mice was~30 min. Predicted immunogenicity was not increased compared to human FV. While rh Tissue Factor, the positive control, resulted in pronounced lung fibrin depositions (mean 121 μg/mL), super FVa did not (6.7 μg/mL), and results were comparable to fibrin depositions with rhFVIIa (7.6 μg/mL) or saline (5.6 μg/mL). Conclusion FVa has an appropriate safety and stability profile for further preclinical development as a prohemostatic against severe bleeding.
INTRODUCTION

Activated super
Factor V ( super FVa) is a novel coagulation FVa variant with potential for clinical development to treat catastrophic bleeding situations such as bleeding in hemophilia, bleeding associated with direct oral anti-coagulants (DOACs), or traumatic bleeding. The molecule was engineered to be resistant against irreversible proteolytic inactivation by activated protein C (APC) involving mutation of all three APC cleavage sites at Arg506, Arg306 and Arg679. In addition, an engineered interdomain disulfide bond (involving His609Cys-Glu1691Cys) connecting the A2 and A3 domains (A2-SS-A3) was introduced (1) , which confers increased specific activity, presumably by preventing domain dissociation as the final step of FVa inactivation (1, 2) .
Super
FVa is a potent molecule to achieve BFVa activity augmentation^, which is emerging as a new concept to enhance hemostasis (2) . FVa is required as an essential cofactor in the prothrombinase complex where it enhances the rate of thrombin generation approximately 10, 000-fold (3). FVa is generated by proteolytic cleavage of the procofactor, factor V, by thrombin, which removes an internal BB domain^resulting in the active FVa (3). However, since FVa is rapidly inactivated by APC, the principle of BFVa activity augmentation^is to deliver APC-inactivation resistant FVa to enhance the prothrombinase complex. This concept was based on several previous observations implying that the prothrombotic FV Leiden mutation changed phenotypic bleeding in hemophilia patients and mice (4, 5) , and that recombin a n t h u m a n ( r h ) F V L e i d e n ( A r g 5 0 6 G l n ) a n d rhFV Cambridge (Arg306Thr), which are partially resistant against inactivation by APC, improved thrombin generation in hemophilia plasma (6, 7) . Although B domain-deleted FV already has some inherent cofactor activity (8) , super FV is being used in fully activated form to remove FV activation as the rate limiting step for its availability in the prothrombinase complex. In addition to APC-resistance, delivery of this activated cofactor appears to be another critical mechanism of the BFVa activity augmentation^strategy, supported by previous observations that clot formation with human plasma-derived FV in FVIII-deficient mice required prior activation of the FV (4) . Since FVa is a cofactor in the prothrombinase complex that only accelerates thrombin generation once factor Xa is enzymatically activated at the site of injury, the prothrombotic risk of BFVa activity augmentation^was deemed low. Taken together, these properties were thought to provide a safe and efficient approach to enhance hemostasis in severe bleeding situations.
Towards that end we studied several APC-inactivation resistant FVa variants for their degree of APC-resistance and their hemostatic properties in hemophilic plasma (2) . We identified one lead candidate, subsequently denoted super FVa, that demonstrated near complete APC inactivation resistance and superior ability to enhance in vitro hemostasis when compared to the other FVa variants (2) . Subsequent studies of super FVa demonstrated its effectiveness to control bleeding in hemophilic mice (2), in wild-type mice with inhibitors against FVIII (9), in bleeding induced by the direct oral FXa inhibitors (DOACs) (10) , and in a mouse trauma model with intensified bleeding by exogenously administered APC (11) . In the trauma model super FVa also rescued survival of the bleeding mice (11) . Additionally, super FVa improved the coagulation parameters in plasma from hemophilia patients with and without inhibitors in bleeding situations, improved thrombin activatable fibrinolysis inhibitor (TAFI)-dependent fibrinolysis inhibition, and demonstrated cooperative effects with rhFVIIa (9) . With respect to hemophilia patients, FVIIa-based clotting factor preparations, e.g., either rhFVIIa (NovoSeven®, Novo Nordisk, Bagsvaerd, Denmark) or a plasma-derived product (FEIBA®, Baxter Biosciences, Westlake Village, USA), are the only available options for patients with inhibitors. Unfortunately, treatment with FVIIa-based agents remains suboptimal and less effective compared to FVIII-based or FIX-based clotting factor concentrates in patients without inhibitors (12) (13) (14) . Additionally, there are currently no effective targeted treatment options available for traumatic bleeding other than blood component replacement (15) 
MATERIALS AND METHODS
Materials
The following reagents were used: thrombin, corn trypsin inhibitor, plasmin (all from Enzyme Research Laboratories, South Bend, IN, USA), purified plasma FV (Haematologic Technology, Burlington, VT, USA), hirudin (Calbiochem, San Diego, CA, USA), thrombin calibrator (Synapse BV, Maastricht The Netherlands), Substrate Z-Gly-Gly-Arg-AMC (Bachem, Bubendorf, Switzerland), rh Tissue Factor (TF), Dade Innovin®, (Dade Behring, Newark, DE, USA), aPTT-XL reagent (Pacific Hemostasis/Fisher Scientific, Middletown, VA, USA), heparin (Baxter, Deerfield, IL, USA), rhFVIIa (Novoseven®, Novo Nordisk, Bagsvaerd, Denmark), pooled normal human plasma (NHP) and FV deficient plasma (FVDP) (George King Bio-Medical, Overland Park, K S, USA), phosphatidylcholine (PC) and phosphatidylserine (PS) (Avanti Lipids, Alabaster, AL, USA).
Recombinant wild-type FV and the super FV variant were purified from conditioned media of stable transfected baby hamster kidney cells by a combination of affinity chromatography using anti-FV 3B1 and HV5101 monoclonal antibodies as described (1, 17) . FV protein concentration was determined by absorbance at 280 nm using FV ε 1% = 16.9 (MW = 174, 000 Da) and enzyme linked immunosorbent assay (ELISA) (Enzyme Research Laboratories, South Bend, IN, USA) according to manufacturer's instructions. FV proteins were activated with 2 nM thrombin for 20 min at 37°C in prothrombinase buffer (50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 150 mM NaCl, 0.5% bovine serum albumin (BSA), 5 mM CaCl 2 and 0.1 mM MnCl 2 ). Activation was terminated by the addition of 1.1 molar equivalent of hirudin (2) .
Coagulation and Thrombin Generation Assays
FVa stability in plasma or in storage buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM CaCl 2 ) with 0.5% BSA was assayed by activity in the activated partial prothrombin time (aPTT) clotting assay in FVDP. Thrombin generation assays were performed as described (18) . Briefly, corn trypsin inhibitor was added to NHP at 1.5 μM, followed by super FVa and rhFVIIa at various concentrations as indicated in the Result section. PCPS vesicles, prepared as described, containing 80% PC and 20% PS (19) , and rhTF were also added. This mix was incubated at 10 min at 37°C before addition of Z-Gly-Gly-Arg-AMC substrate and calcium to initiate the reaction. Each reaction was 100 μL total volume containing 50% plasma. Final concentrations were 0.2 pM rhTF, 4 μM PCPS vesicles, 7.6 mM CaCl 2 and 0.5 mM Z-GGR-AMC. Fluorescence was measured at excitation/emission wavelengths of 360/460 nM using the Gemini EM fluorescent plate reader (Molecular Devices Corporation, Menlo Park, CA, USA). The endogenous thrombin potential (ETP), defined as the area under the curve (AUC) and the thrombin peak height were determined as described (20) .
Animals
All animal protocols were carried out as approved by the institutional animal care and use committee of The Scripps Research Institute. Several breeding pairs of FVIII-deficient mice (Balb/c background) were a generous gift of Dr. David Lillicrap. Male or female FVIII-deficient mice, aged ≥ 8 weeks, were used to determine the pharmacokinetics of FV variants. Female BALB/c mice, aged ≥ 8 weeks, were used for the lung fibrin deposition assay.
In Vivo Dosing of FVa Variants
In vivo super FVa dosing was based on units/kilogram (U/kg), determined as prothrombinase cofactor activity, whereby the activity of 20 nM wild-type FVa (FV plasma concentration) was defined as one Unit (2) . Dosing by activity is the usual method for clinical administration of clotting factors (such as FVIII), thereby correcting for variations of specific activity in biological material. For these experiments 200 U/kg corresponded to 0.7 mg/kg super FVa.
In Vivo Fibrin Deposition in Lung Thromboembolism
Fibrin deposition in the lungs was measured following retroorbital injection of the desired agent in a volume of 100 μL into Balb/c mice as described by Hendrickx et al. (21) . Briefly, mice were weighed and 110 mg/kg ketamine and 16 mg/kg xylazine were administered intraperitoneally. Mice were maintained in deep anesthesia with 1-2% isoflurane and immobilized on a dissection pad. Approximately 15 min after the injection of the desired agent the abdomen was opened, and the inferior vena cava (IVC), heart and lungs were exposed. At 20 min 50 μL of 10,000 U/ml heparin was injected into the IVC to stop coagulation. After 10-15 s the IVC was cut below the liver, and 10-11 ml of saline with 10 U/mL heparin was injected slowly into the right ventricle to flush out the lungs. Lungs were harvested immediately thereafter and flash frozen on dry ice.
Fibrin was extracted from the lungs as follows: 0.5 ml cold phosphate buffered saline (PBS) was added to the lungs in a 1.5 ml tube. Lungs were diced with dissecting scissors, sonicated on wet ice for 2 min, alternating 2 s on and 3 s off using a microtip sonicator probe. Tubes were centrifuged at 15,000 g for 10 min at 4°C. The pellet was weighed, washed twice with 500 μL PBS and resuspended in 4 μL PBS per mg of weight. Plasmin (100 nM final concentration) was added, followed by incubation at 37°C for 4 h, vortexing every hour. The suspension was then centrifuged for 20 min at 15,000 g, and the supernatant was assayed at 1:90 dilution for fibrin degradation products using the mouse fibrinogen ELISA kit (Immunology Consultants Laboratory, Portland, OR, USA). The standard was provided with the kit.
In Vivo Pharmacokinetics
FVIII-deficient Balb/c mice were anesthetized with 5% isoflurane.
Super FVa, super FV or plasma FV at the desired concentration were injected retro-orbitally in 100 μL saline. Blood was sampled retro-orbitally at various time points using heparinized micro-capillaries, which were immediately evacuated into~1/10 volume 3% NaCitrate. Every mouse was sampled at 2 min from the opposite eye as the injection for a Bzero^point, and then again at one additional time point from the same eye as the injection. Factor V concentration was determined by ELISA using the respective FVa variant as standard.
Prediction of Antigenicity/Immunogenicity of super FVa B cell responses were predicted with two methods. First, prediction of β-turns in proteins was used to compute the location of B-cell epitopes (22) . Then standard parameters were used for both sequences and the difference between predictions of B-cell epitopes ( super FVa -FVa) was directly computed in Bepitope (23) . The second method (Bepipred) combines a hidden Markov model with classical propensity scale methods (24) . Using Bepipred, the sequences of wild-type FVa and super FVa were used for predicting linear B-cell epitopes and the difference was computed residue by residue. The NetCTL tool was used for T-cell epitope prediction. NetCTL is available in the IEDB analysis resource (25) . NetCTL is a predictor of T cell epitopes based on neural networks (26) . Differences in T-cell epitope prediction were computed by submitting both super FVa and normal FVa sequences to all the 12 supertypes.
Statistics
All experiments were repeated 2-5 times. Statistical significance between groups was ascertained by one-way ANOVA followed by Dunnett's multiple comparison analysis using GraphPad Prism (San Diego, CA). Error bars represent the standard deviation (calculations performed in Excel).
RESULTS
Stability of super FVa Compared to Wild-Type FVa in Plasma and in Storage Buffer
The disulfide bond between the A2 and A3 domains confers enhanced stability of super FVa relative to wild-type FVa, whereas removal of three APC cleavage sites (1,2) provides resistance to proteolysis, most notably resistance to inactivation by APC. Here, we demonstrated notably improved stability of super FVa compared to wild-type FVa by comparing the retention of activity following incubation in citrated NHP or storage buffer at 37°C for up to 8 or 30 h, respectively. The remaining activity at various time points was determined by the ability of each FVa variant to shorten the aPTT of FVDP. In NHP at 500 pM super FVa had greatly enhanced stability with a half-life of 4.9 h. Wild-type FVa was very unstable in comparison and decayed in a biphasic curve. The first half-life was 0.24 h with a plateau at 36%, and the second half-life was 2.9 h with a plateau at zero (Fig. 1a) .
In storage buffer in the presence of 0.5% BSA to prevent loss of FV through adsorption, super FVa and wild-type FVa (both 100 nM) were both relatively stable over the tested time period (30 h). However, super FVa was more stable compared to wild-type FVa and maintained 100% activity over the 30 h time course, whereas wild-type FVa lost approximately 40% of its activity (Fig. 1b) . Fig. 2) . In contrast to plasma FV, which has a full B domain, recombinant super FV is missing most of the B domain, suggesting that presence of a full B domain helps to reduce clearance. FVa to NHP was studied over a concentration range from 6 to 400 nM, which exceeded the maximum estimated plasma concentration (~100 nM) that previously achieved complete hemostasis after injury in hemophilic mice or wild-type mice treated with FVIII inhibitors (2, 9) . Thrombin generation with super FVa at these same concentrations was also tested in the presence of 40 nM rhFVIIa (approximate therapeutic plasma concentration after infusion of 90 μg/kg) to evaluate cooperative effects (9) . Thrombin generation is presented as both maximum thrombin generation peak height and ETP ( Fig. 3a and b) .
In Vivo
Thrombogenicity of
Super FVa had only a small effect on thrombin peak height in normal plasma that was less than that of 40 nM rhFVIIa.
Super
FVa did increase thrombin peak height in the presence of rhFVIIa but this effect reached a plateau at 120% of rhFVIIa alone (Fig. 3a) .
FVa had a small effect on ETP in the absence and presence of rhFVIIa (Fig. 3b) , but this effect of super FVa was saturated at increasing super FVa concentrations and never exceeded 150% of the ETP in normal plasma regardless of whether rhFVIIa was present or not (Fig. 3b) . Additionally, in the absence of rhFVIIa the ETP returned to normal as the super FVa concentration increased (Fig. 3b) . These findings indicate that thrombin generation in NHP in vitro, under experimental conditions where substrates are not continuously replaced, was subject to saturation.
The in vivo thrombogenicity of i.v. injected super FVa was studied in a murine model of pulmonary embolism that quantifies fibrin deposition in lungs of wild-type Balb/C mice (n = 4-5 per group). Fibrin deposition after i.v. administration of super FVa (200 U/kg; 100 nM estimated plasma concentration) was compared to fibrin deposition after i.v. administration of rhTF as the positive control. The i.v. doses of rhTF ranged from 0.4 to 16 pmol/kg, and all resulted in arrested breathing. The i.v. injection of saline served as the negative control. We also tested thrombogenicity of rhFVIIa injected i.v. at 3 mg/kg (Fig. 4) . This dose exceeds the approved dose of rhFVIIa for treatment of hemophilia patients with inhibitors approximately 30-fold and resulted previously in partially corrected hemostasis in Balb/c mice after tail clip (9) . While the injection of rhTF resulted in a pronounced increase in fibrin deposition in the lungs relative to saline (mean 120.5 μg/mL vs. mean 5.5 μg/mL, one-way ANOVA with Dunnett's multiple comparison test, p < 0.001),
super FVa (mean 6.7 μg/mL) and rhFVIIa (mean 7.6 μg/mL) did not significantly increase fibrin deposition relative to saline. Therefore, neither results from the in vitro nor in vivo assays suggested excessive thrombogenic potential of super FVa or thrombogenicity higher than observed with high doses of rhFVIIa Figs. 3 and 4.
Predicted Antigenicity and Immunogenicity of super FVa
Antigenicity is the capacity of an antigen, such as a foreign protein, to be recognized by an antibody, whereas immunogenicity is the capacity of an antigen to elicit immune response (including antibody formation). Exposure to an engineered protein, such as super FVa, bears an unknown risk of antibody formation against FV-related molecules that cannot be assessed in animal studies due to species related immunogenicity.
One approach to predict immunogenic risk of a molecule is B-and T-cell specific epitope prediction analysis. Both, B-cell and T-cell responses have to be evaluated for the propensity to produce antigen-specific antibodies and/or to activate cytotoxic pathways to eliminate the antigen.
Regarding B-cell epitope prediction, it is important to determine the difference in antigenicity between wild-type and super FVa. Two prediction methods were used. In the first, prediction of β-turns was used to compute the location of Bcell epitopes followed by use of Bepitope to calculate the difference between super FVa and FVa Fig. 5a . Depending on the β-turn scale used (named 33 or EE), a modest increase in the putative epitopes located at either position 506 or 1691 was noticed, as well as a consistent decrease in every other sequence change most notably in the C-terminus (replacement of the glycosylation site). In the second method the Bepipred tool was used to predict epitopes and compute differences between B-cell epitopes Fig. 5b . Bepipred indicated that the minimum and maximum changes in B-cell epitopes ranged from −0.61 to +0. 17 . Negative values indicate a decrease in antigenicity. The maximum increase in antigenicity of super FVa was well below the threshold of the Bepipred protocol (+0.35). Consequently, both methods used to predict Bcell epitope do not suggest increased antigenicity of the super FVa sequence relative to the wild-type FVa sequence. NetCTL was used to predict T-cell epitopes and differences in T-cell epitope prediction were computed by submitting both super FVa and normal FVa sequences to all the 12 supertypes Fig. 5c (26) . Overall, the maximum range of variation between both sequences was −1.65 and +0.49. As with B-cell epitopes, negative values indicate a reduction in immunogenicity. The maximum value difference (+0.49) was therefore still below the threshold used in NetCTL and did not identify a putative T-cell epitope (+0.75). These results suggest that there are no or very limited changes in T-cell epitopes, predicting no major changes in immunogenicity.
Finally, structural properties of the engineered disulfide bond have been analyzed using surface area with Naccess (Hubbard et al., personal communication) and atomic depth computation (27) on the complete model of FVa (28) . The relative surface accessibility (RSA) calculated is 19 A 2 for Glu1691 and 15 A 2 for His609 whereas the atomic depth of Cβ atoms of Glu1691 and His609 are −3.9 and −6.2 Å, respectively. These values indicate that both residues are buried within the protein and thus should not affect the surface properties of super FVa.
DISCUSSION
Super
FVa is a newly developed, engineered clotting factor molecule to enhance hemostasis in severe bleeding situations. Findings reported here demonstrate that super FVa is stable in storage buffer and human plasma ex vivo.
FVa did not exhibit enhanced antigenicity and immunogenicity in B-and T-cell epitope prediction models when compared to the wildtype FVa sequence, nor was thrombogenicity enhanced compared to rhFVIIa in NHP and in a murine model of pulmonary embolism, where the injection of rh TF served as a positive control.
Despite its activated status, super FVa was very stable in solution. When incubated at 37°C in storage buffer it retained 100% of activity over the tested 30 h time course, whereas wild-type FVa lost approximately 40% of its activity. To also test biological stability in human plasma, super FVa was incubated in citrated NHP at 37°C. Consistent with the findings in storage buffer, super FVa lost activity slowly with a half-life of 5 h, whereby~20% of activity were still retained at 8 h. In contrast, wild-type FVa was unstable, rapidly lost activity with a half-life of~30 min, and retained less than 20% of activity at 2 h. It has been previously suggested that, in addition to APCresistance, enhanced stability contributes to the superior hemostatic properties of super FVa. This was supported by observations that FVa variants with the disulfide bond had significantly higher specific activity in purified prothrombinase assays compared to the same variants without the disulfide bond (1,2). The findings reported here confirm that the disulfide bond between the A2 and A3 domains confers enhanced stability of super FVa relative to wild-type FVa. To explore the circulating plasma half-life in vivo, half-life studies were performed in mice. FVIII-deficient mice (Balb/c background) were employed for this purpose since many of the in vivo bleeding models had been completed in this mouse strain. The half-life of the half-life of super FVa was comparable to super FV is highly encouraging since endogenously produced FVa is rapidly degraded with a half-life believed to be on the order of minutes only (29) . These findings also establish that the half-life of super FVa can be studied in rodents, which is important for further preclinical development. Previous studies demonstrated a wide range of variability concerning the decay of human clotting factors in rodents, which is mostly faster compared to what is observed in human circulation (30) (31) (32) . Therefore, extrapolating from the measured half-life of human plasma FV in mice (~2 h) compared to the known half-life of FV in human plasma (~12-36 h), the half-life of super FVa in humans could potentially be at least 3 h. Notwithstanding determination of half-life in human volunteers, half-life estimates at this stage of preclinical development are important to predict feasibility or usefulness of super FVa in certain indications. Generally, a shorter half-life with the opportunity to rapidly Bswitch coagulation on and off^is considered advantageous for bleeding associated with DOACs or traumatic bleeding, where patients suffer from underlying prothrombotic conditions or a coagulopathy. In contrast, a longer half-life may be desirable for bleeding in hemophilia to avoid repetitive dosing or afford prophylactic administration. For instance, the circulating half-life of zymogen-like FX currently developed for intracranial bleeding is only~60 min in mice (33) , whereas long-acting FVIIa molecules with half-life extension beyond 4-6 h are in development to afford prophylactic treatment in hemophilia patients with inhibitors to prevent joint bleeding (34, 35) . Based on current observations, the extrapolated halflife of super FVa may fall into an intermediate range that may be suitable for a variety of conditions.
There was no finding of thrombogenicity in a mouse model (wild-type Balb/c) of pulmonary embolism, quantifying fibrin depositions in the lung after injection of a single dose of super FVa (200 U/kg). This dose results in a plasma concentration of~100 nM based on the assumption that the plasma volume of a 20-25 g mouse is~1 mL. This dose was the highest dose that previously resulted in complete hemostasis in mouse models of bleeding (2,9,11), and exceeds the plasma concentration of circulating FV (~20 nM) five times. Results with super FVa were similar compared to what was observed after injection of 3 mg/kg rhFVIIa, which is a~30-fold higher dose than approved for human use, but necessary to achieve partial hemostasis in mice (9, 30) . Also, thrombin generation in NHP employing super FVa at concentrations as high as 400 nM was only marginally increased, even when combined with rhFVIIa at therapeutic concentrations for human use. Taken together, these findings support that super FVa does not result in undue thrombin generation in vitro and in vivo, out of proportion to what is experienced with rh FVIIa.
The antigenic and immunogenic potential of recombinant engineered molecules is an important concern for protein replacement therapies. The exposure to an engineered protein, such as super FVa, bears an unknown risk of antibody formation against FV-related molecules that cannot be assessed in animal studies due to species related immunogenicity. Final assessment of immunogenicity for all such molecules can therefore only be accomplished in human studies. However, the potential for immunogenicity can be predicted to a certain extent by B-and T-cell epitope modelling, whereby a positive signal would substantiate concerns and possibly exclude a molecule from further development. Testing of super FVa in the B-and T-cell epitope prediction model did not yield increased antigenicity or immunogenicity of the super FVa sequence relative to the wild-type FVa sequence, thus suggesting a low potential for antibody formation. Of note, antigenicity and immunogenicity are clinically most relevant when exposure to a molecule is frequent and chronic such as in hemophilia to prevent and treat bleeding episodes. There, formation of inhibitory antibodies to exogenous FVIII or FIX preparations is observed at a median of 10 exposure days in~30% of patients with FVIII-deficiency and~5% of patients with FIX-deficiency (36, 37) . Inhibitor formation with rh FVIIa is rare, but has been observed with a modified, higher potency FVIIa product following repeated exposure over many months (38) . For single short-term use such as for traumatic bleeding or DOAC-associated bleeding the risk of inhibitor formation appears therefore negligible and less relevant.
CONCLUSION
super FVa appears to be a stable molecule in buffer solution and plasma, with a favourable pharmacokinetic profile in mice, consistent with its previously observed therapeutic hemostatic effects (2, 9, 11) . The lack of thrombogenicity in mice, and the lack of antigenicity and immunogenicity in B-and T-cell prediction models are critical findings that permit the continuation and advancement of super FVa in preclinical and clinical development as novel, versatile prohemostatic agent for severe bleeding situations.
ACKNOWLEDGMENTS AND DISCLOSURES
This work was funded by grant support from an Early Career Development Award from Bayer Hemophilia (AvD), by National Institutes of Health grants HL104165 (LOM) and HL03195 and HL052246 (JHG).
COMPLIANCE WITH ETHICAL STANDARDS
Disclosures AvD has received honoraria for participating in scientific advisory board panels, consulting, and speaking engagements for Baxalta, Pfizer, Biogen, CSL-Behring, Novo Nordisk, and Grifols. LOM has received research funding and honoraria for participating in scientific advisory board panels for Bayer. UCSD and TSRI hold intellectual property rights related to super FVa on which AvD, AJG, JHG, and LOM are listed as inventors. AvD, AJG, and LOM are founders of Hematherix LLC., a biotech company that is developing super FVa therapy for bleeding complications. AvD and LOM are members of the Board of Directors of Hematherix LLC.
